Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-29T17:29:57.451Z Has data issue: false hasContentIssue false
  • English
  • Français

Placebo-controlled relapse prevention trials in unipolar depression

Published online by Cambridge University Press:  16 April 2020

P. Bech
P. Bech*
Affiliation:
Psychiatric Research Unit, Frederiksborg General Hospital, Hillerod, Denmark

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Among the treatment modalities in the acute therapy phase of a major depressive episode, ECT (electroconvulsive therapy) has the highest response rate (90%), but also the highest relapse rate in the continuation phase over the next 6 months (65%). Placebo has the lowest response rate (45%), but the highest pharmacological relapse rate (50%). The SSRIs seem to have the lowest relapse rate compared to imipramine (12% versus 30%). Both the SNRIs and mirtazapine (the “dual action” drugs) have higher relapse rates (20%) although they have a higher response rate than the SSRIs (70% versus 60%).

Type
S31. Symposium: 25 Years of Experiences with Various Types of Antidepressants: The Danish University Antidepressant Group
Information
European Psychiatry , Volume 22 , Issue S1: 15th AEP Congress - Abstract book - 15th AEP Congress , March 2007 , pp. S50
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.